Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 31, 2013. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Purchased: 795,500 Ordinary Shares on May 31, 2013.
- Price Range: Highest price paid was 1,727.0 pence per share; lowest price paid was 1,692.5 pence per share.
- Treasury Holdings (Settled): 502,507,887 shares (9.26% of total issued share capital).
- Treasury Holdings (Including Unsettled): 504,734,512 shares (10.25% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,926,446,166 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 795,500 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.25% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (502,507,887 settled) against the company's latest capital structure.
- Confirm the calculation of total voting rights (4,926,446,166 shares in issue) for disclosure threshold assessments.
- Review the price paid per share (1,692.5 to 1,727.0 pence) relative to the market price on May 31, 2013.
- Note that this filing does not contain operational or financial performance data for the period.